Importantly, the dependency of tumor cells on FAK signaling following mTORC1 blockade was only revealed using in vivo models of rapamycin-resistant tumors, indicating that drug resistance extends beyond tumor-cell-intrinsic pathways of adaptive or acquired resistance to include the ECM. The gene discussed is PTK2; the disease is neoplasm.